Sale

Hypophosphatasia Treatment Market

Global Hypophosphatasia Treatment Market Share, Size, Growth, Forecast, Analysis: By Type: Perinatal, Infantile, Childhood, Adult, Odonto-hypophosphatasia, Pseudo-hypophosphatasia; By Diagnosis Method: X-rays, Biochemical Tests, Others; By Treatment Method; By Treatment Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Hypophosphatasia Treatment Market Outlook

The global primary hypophosphatasia treatment market is expected to grow at a CAGR of 5.10% during the forecast period of 2024-2032. The market is driven due to the growing awareness of the rare disease, a strong product pipeline, and increased financial support for researchers developing new innovative drugs for hypophosphatasia.

 

hypophosphatasia treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Hypophosphatasia Insights

Hypophosphatasia (HPP) is a rare genetic disorder characterised by impaired bone and tooth mineralization (calcification). Mineralization is the process by which bones and teeth absorb the calcium and phosphorus required for proper hardness and strength.

 

The six major clinical forms are distinguished primarily by the age at which symptoms appear and a diagnosis is made like perinatal HPP, infantile HPP, childhood HPP, adult HPP, odontohypophosphatasia, and pseudohypophosphatasia. These forms are referred to by their decreasing severity.

 

Mutations in the ALPL gene can cause HPP. Genes encode instructions for the production of proteins that serve vital functions in the body. When a protein is mutated, it can become faulty, inefficient, or even absent, as in HPP. Depending on the function of the protein, one or more organ systems of the body may be jeopardised.

 

HPP is diagnosed by identifying its symptoms and complications, which begins with a thorough patient history. A thorough clinical examination reveals HPP signs, which are supported by routine x-rays and a variety of laboratory tests, including biochemical studies. For those who are familiar or experienced with this disorder, HPP is frequently easy to identify. 

 

Most physicians, understandably, have little or no knowledge of HPP which leads to a frustrating delay in diagnosis. Commercial laboratories now offer genetic mutation analysis of the ALPL gene to support a diagnosis of HPP.

 

According to the market research report, the hypophosphatasia treatment market can be categorised into the following segments:

 

hypophosphatasia treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Type

  • Perinatal
  • Infantile
  • Childhood
  • Adult
  • Odontohypophosphatasia
  • Pseudohypophosphatasia

 

Market Breakup by Diagnosis Method

  • X-rays
  • Biochemical Tests
  • Chorionic Villus Sampling (CVS)
  • Ultrasounds
  • Vitamin B6 Test

 

Market Breakup by Treatment Method

  • Medications
    • Nonsteroidal anti-inflammatory drugs (NSAIDs)
    • Vitamin B6
    • Others
  • Dental Care
  • Physical Therapy
  • Occupational Therapy

 

Market Breakup by Treatment Channel

  • Public
  • Private

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

hypophosphatasia treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Hypophosphatasia Treatment Market Epidemiology

HPP affects both men and women equally. Severe HPP is estimated to affect one in every 100,000 live births in Canada. The overall incidence and prevalence of the various forms of HPP are unknown or poorly understood. Milder cases may go undetected or be misdiagnosed. HPP is most common in the Mennonite population of Canada, is relatively common in Japan, and appears to be rare in people of Black ancestry.

 

Global Hypophosphatasia Therapeutic Landscape

Asfotase alfa (Strensiq) was approved by the US Food and Drug Administration (FDA) as the first medical treatment for perinatal, infantile, and juvenile-onset HPP. In the United States, patients of any age with pediatric-onset HPP are eligible for this bone-targeted tissue-nonspecific alkaline phosphatase (TNSALP) replacement therapy administered subcutaneously.

 

Global Hypophosphatasia Treatment Market Drivers

The growing number of hypophosphatasia patients, a family history of hypophosphatasia, a strong product pipeline, and increased financial support for researchers developing new innovative drugs for hypophosphatasia treatment are expected to drive the hypophosphatasia market during the forecast period. Furthermore, an increase in special designation from regulatory authorities to provide treatment to patients as soon as possible is boosting the market.

 

Hypophosphatasia Investigational Therapies

Teriparatide, a type of parathyroid hormone, has been given "off-label" to several adults with HPP complicated by metatarsal stress fractures or femoral pseudo fractures, resulting in fracture healing. Children are not permitted to use the drug. More research is required to determine teriparatide's long-term safety and effectiveness in the treatment of HPP. To treat severe HPP, bone marrow cell transplantation has been used. 

 

Preliminary short-term results from the use of an anti-sclerostin antibody for HPP have also been reported. Sclerostin is a protein found in osteocytes, which are cells embedded in bone. Sclerostin aids in the reduction (downregulation) of osteoblasts. Sclerostin-specific antibodies have been shown to increase bone mass in osteoporosis patients.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global hypophosphatasia treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:  

 

  • Kirin Holdings Company
  • Vericel Corporation
  • Mereo BioPharma Group plc
  • Novartis AG
  • Bayer AG
  • AM-Pharma B.V.
  • Alexion
  • Pfizer, Inc.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Diagnosis Method
  • Treatment Method
  • Treatment Channel
  • Region
Breakup by Type
  • Perinatal
  • Infantile
  • Childhood
  • Adult
  • Odonto-hypophosphatasia
  • Pseudo-hypophosphatasia
Breakup by Diagnosis Method
  • X-rays
  • Biochemical Tests
  • Chorionic Villus Sampling (CVS)
  • Ultrasounds
  • Vitamin B6 Test
Breakup by Treatment Method
  • Medications
  • Dental Care
  • Physical Therapy
  • Occupational Therapy
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis 
  • Porter's Five Forces Analysis 
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Kirin Holdings Company
  • Vericel Corporation
  • Mereo BioPharma Group plc
  • Novartis AG
  • Bayer AG
  • AM-Pharma B.V.
  • Alexion
  • Pfizer, Inc.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
2    Research Methodology
3    Executive Summary
4    Hypophosphatasia Overview

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Model 
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Current Scenario Evaluation
    6.1    Emerging Therapies and Clinical Trials Synopsis
    6.2    Patent Landscape and Impact
    6.3    Cost of Treatment
    6.4    Others
7    Challenges and Unmet Needs
    7.1    Treatment Pathway Challenges
    7.2    Compliance and Drop- out Analysis
    7.3    Awareness and Prevention Gaps
8    Global Hypophosphatasia Treatment Market
    8.1    Global Hypophosphatasia Treatment Market Overview
    8.2    Global Hypophosphatasia Treatment Market Analysis 
        8.2.1    Market Overview
            8.2.1.1    Global Historical Hypophosphatasia Treatment Market Value (2017-2023) 
            8.2.1.2    Global Forecast Hypophosphatasia Treatment Market Value (2024-2032)
        8.2.2    Global Hypophosphatasia Treatment Market by Type
            8.2.2.1    Market Overview
                8.2.2.1.1    Perinatal 
                8.2.2.1.2    Infantile
                8.2.2.1.3    Childhood
                8.2.2.1.4    Adult
                8.2.2.1.5    Odonto-hypophosphatasia
                8.2.2.1.6    Pseudo-hypophosphatasia
        8.2.3    Global Hypophosphatasia Treatment Market by Diagnosis Method 
            8.2.3.1    Market Overview
                8.2.3.1.1    X-rays
                8.2.3.1.2    Biochemical Tests
                8.2.3.1.3    Chorionic Villus Sampling (CVS)
                8.2.3.1.4    Ultrasounds
                8.2.3.1.5    Vitamin B6 Test 
        8.2.4    Global Hypophosphatasia Treatment Market by Treatment Method
            8.2.4.1    Market Overview
                8.2.4.1.1    Medications
                    8.2.4.1.1.1    Nonsteroidal anti-inflammatory drugs (NSAIDs)
                    8.2.4.1.1.2    Vitamin B6 
                    8.2.4.1.1.3    Others
                8.2.4.1.2    Dental Care
                8.2.4.1.3    Physical Therapy
                8.2.4.1.4    Occupational Therapy
        8.2.5    Global Hypophosphatasia Treatment Market by Treatment Channel
            8.2.5.1    Market Overview
                8.2.5.1.1    Public
                8.2.5.1.2    Private
        8.2.6    Global Hypophosphatasia Treatment Market by Region
            8.2.6.1    Market Overview
                8.2.6.1.1    North America
                8.2.6.1.2    Europe 
                8.2.6.1.3    Asia Pacific
                8.2.6.1.4    Latin America
                8.2.6.1.5    Middle East and Africa
9    North America  Hypophosphatasia Treatment Market
    9.1    Market Share by Country
    9.2    United States of America
        9.2.1    Historical Trend (2017-2023)
        9.2.2    Forecast Trend (2024-2032)
    9.3    Canada
        9.3.1    Historical Trend (2017-2023)
        9.3.2    Forecast Trend (2024-2032)
10    Europe Hypophosphatasia Treatment Market
    10.1    Market Share by Country
    10.2    United Kingdom
        10.2.1    Historical Trend (2017-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    Germany
        10.3.1    Historical Trend (2017-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    France
        10.4.1    Historical Trend (2017-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Italy
        10.5.1    Historical Trend (2017-2023)
        10.5.2    Forecast Trend (2024-2032)
    10.6    Others
11    Asia Pacific Hypophosphatasia Treatment Market
    11.1    Market Share by Country
    11.2    China
        11.2.1    Historical Trend (2017-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    Japan
        11.3.1    Historical Trend (2017-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    India
        11.4.1    Historical Trend (2017-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    ASEAN
        11.5.1    Historical Trend (2017-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Australia
        11.6.1    Historical Trend (2017-2023)
        11.6.2    Forecast Trend (2024-2032)
    11.7    Others
12    Latin America Hypophosphatasia Treatment Market
    12.1    Market Share by Country
    12.2    Brazil
        12.2.1    Historical Trend (2017-2023)
        12.2.2    Forecast Trend (2024-2032)
    12.3    Argentina
        12.3.1    Historical Trend (2017-2023)
        12.3.2    Forecast Trend (2024-2032)
    12.4    Mexico
        12.4.1    Historical Trend (2017-2023)
        12.4.2    Forecast Trend (2024-2032)
    12.5    Others
13    Middle East and Africa Hypophosphatasia Treatment Market
    13.1    Market Share by Country
    13.2    Saudi Arabia
        13.2.1    Historical Trend (2017-2023)
        13.2.2    Forecast Trend (2024-2032)
    13.3    United Arab Emirates
        13.3.1    Historical Trend (2017-2023)
        13.3.2    Forecast Trend (2024-2032)
    13.4    Nigeria
        13.4.1    Historical Trend (2017-2023)
        13.4.2    Forecast Trend (2024-2032)
    13.5    South Africa
        13.5.1    Historical Trend (2017-2023)
        13.5.2    Forecast Trend (2024-2032)
    13.6    Others
14    Global Hypophosphatasia Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces Model
    14.4    Key Demand Indicators 
    14.5    Key Price Indicators
    14.6    Industry Events, Initiatives, and Trends  
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Kirin Holdings Company
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2    Vericel Corporation
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Mereo BioPharma Group plc
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Novartis AG
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    Bayer AG
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    AM-Pharma B.V.
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    Alexion
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    Pfizer, Inc.
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
16    Hypophosphatasia Treatment Market- Distribution Model (Additional Insight)
    16.1    Overview 
    16.2    Potential Distributors 
    16.3    Key Parameters for Distribution Partner Assessment 
17    Payment Methods (Additional Insight)
    17.1    Government Funded
    17.2    Private Insurance
    17.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

qThe market is likely to grow at a CAGR of 5.10% during the forecast period of 2024-2032.

The market growth is driven by the growing awareness of the rare disease, a strong product pipeline, and increased financial support for researchers developing new innovative drugs for hypophosphatasia.

qNorth America is the dominating region in the global market owing to the rising demand for the treatment with the increased awareness about the disorder.

Kirin Holdings Company, Vericel Corporation, Mereo BioPharma Group plc, Novartis AG, Bayer AG, AM-Pharma B.V., and Alexion, Pfizer, Inc., among others are the leading companies in the market.

Lack of awareness of the treatment and a rise in the absence of information about the treatments will restrain the growth of hypophosphatasia treatment market.

Within the first year of life, mortality rates among patients with perinatal or infantile HPP ranged from 58 to 100 percent.

Adults with HPP may be diagnosed when routine laboratory testing reveals low serum ALP levels or when being evaluated for osteoporosis or fractures.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER